Oxford BioDynamics, a revenue-generating biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, announces that it has entered into a development agreement with two of the top 10 global pharmaceutical companies, that are collaborating on an anti PD-L1 therapy.

Oxford BioDynamics will identify biomarkers in whole blood of non-small cell lung carcinoma (NSCLC) patients to assist in differentiating between responders and non-responders to an anti PD-L1 therapy, using its EpiSwitch biomarker platform.

The agreement has the potential to be extended in the form of a licensing agreement, which would see the development of an EpiSwitch-class blood-based test, based on the work undertaken as part of the current agreement, for use by the pharmaceutical companies.

Financial terms of the agreement are not disclosed.

Christian Hoyer Millar, Chief Executive Officer of Oxford BioDynamics, said: “We are very pleased to be working with these prestigious pharmaceutical companies to help them differentiate between responders and non-responders to an anti PD-L1 therapy.”

“The momentum of EpiSwitch, as the leading epigenetic platform, continues to grow and the fact that our EpiSwitch platform is ideally positioned to aid these pharmaceutical companies only validates the platform further. We are excited by the potential of this agreement and we look forward to working with these companies with the aim of improving their development outcomes.”